The effect of methotrexate in patients with ectopic pregnancy

Comparative study of the effect of methotrexate with and without the addition of letrozole in patients with ectopic pregnancy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250302064899N1

Enrollment

Registered

2025-03-09

Start date

2025-04-21

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic pregnancy. Ectopic pregnancy

Interventions

Intervention 1: Intervention group: Treatment with methotrexate ampoules manufactured by Kharazmi Pharmaceutical Company at a dose of 1 mg per kilogram of body weight and administered as a single dose

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Informed consent Ectopic pregnancy Stable hemodynamic

Exclusion criteria

Exclusion criteria: Methotrexate allergy

Design outcomes

Primary

Measure	Time frame
Pregnancy termination. Timepoint: 2 months after the start of the study. Method of measurement: Blood Bhcg level.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParisa Modirifard

Esfahan University of Medical Sciences

Parisamodiri73@gmail.com+98 31 3668 0048

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026